A groundbreaking study led by WEHI and the Peter MacCallum Cancer Centre has identified two proteins critical for the development of B-cell acute lymphoblastic leukaemia, offering new treatment possibilities. By targeting these proteins, researchers were able to kill leukaemia cells and stop their growth in lab models, paving the way for future clinical trials.